Regeneron Rips Amgen's 'Bundling Scheme' Amid IP Feud
Regeneron Pharmaceuticals Inc. has launched a new antitrust lawsuit accusing Amgen of an illegal "bundling scheme" aimed at destroying the market for Regeneron's cholesterol medication Praluent and boosting sales of its...To view the full article, register now.
Already a subscriber? Click here to view full article